Giuseppe
Emeritus
Italy, Influenza - Virological Surveillance Update - Week 06/2011 (Ministry of Health, Feb 16 2011, extract, edited): 65.9% of isolates were H1N1 (2009)
[Source: Ministry of Health, full PDF document (in Italian), (LINK). Translated by the Mod.(IOH), edited.]
Italy, Influenza - Virological Surveillance Update - Week 06/2011
16 February 2011
Clinical samples collection activity continues through Influnet laboratories network.
During current week (06/2011), eight hundred and seventy (870) clinical samples have been collected by network's laboratories.
Among these, three hundred forty-nine (349 [40,1%]) were positive for influenza virus.
Ninety-three (93 [26,6%]) were type B, two hundred and thirty (230 [65,9%]) were type A H1N1 (2009), three (3) were A(H3N2) and twenty-three (23) were not yet subtyped.
Table 1 - Virological Surveillance of Influenza - Cumulative Number of Isolates per Week and Type/Subtype (since the start of the season, Week 46/2010
[Type-Subtype / Week (number of isolates): 46 / 47 / 48 / 49 / 50 / 51 / 52 / 01 / 02 / 03 / 04 / 05 / 06, Total]
ANTIVIRAL DRUGS RESISTANCE SURVEILLANCE - ITALY
Since the start of the 2010/2011 influenza season, forty three (43) influenza A(H1N1) 2009 viruses have been tested for antivirals susceptibility; among these, two (2) (4.6%) were resistant to the neuraminidase inhibitor oseltamivir but retained susceptibility to zanamivir.
The two viruses were collected from two hospitalized children in Parma, who were treated with the drug oseltamivir.
Genetic sequence analysis revealed that the two viruses possessed the H274Y substitution on neuraminidase, that confers resistance to oseltamivir.
Drug resistance was confirmed for these viruses through enzyme assays (MUNANA).
In addition, four A(H3N2) and 28 type B viruses have been confirmed susceptible to both oseltamivir and zanamivir.
(...)
-
-----
[Source: Ministry of Health, full PDF document (in Italian), (LINK). Translated by the Mod.(IOH), edited.]
Italy, Influenza - Virological Surveillance Update - Week 06/2011
16 February 2011
Clinical samples collection activity continues through Influnet laboratories network.
During current week (06/2011), eight hundred and seventy (870) clinical samples have been collected by network's laboratories.
Among these, three hundred forty-nine (349 [40,1%]) were positive for influenza virus.
Ninety-three (93 [26,6%]) were type B, two hundred and thirty (230 [65,9%]) were type A H1N1 (2009), three (3) were A(H3N2) and twenty-three (23) were not yet subtyped.
Table 1 - Virological Surveillance of Influenza - Cumulative Number of Isolates per Week and Type/Subtype (since the start of the season, Week 46/2010
[Type-Subtype / Week (number of isolates): 46 / 47 / 48 / 49 / 50 / 51 / 52 / 01 / 02 / 03 / 04 / 05 / 06, Total]
- INFLUENZA A - 0 - 4 - 3 - 1 - 8 - 20 - 41 - 73 - 177 - 284 - 291 - 240 - 256 - 1.398
- A (not yet subtyped) - ... - 1 - ... - ... - ... - 2 - 2 - 4 - 23 - 32 - 33 - 28 - 23 - 148
- A/H3N2 - ... - ... - ... - 1 - 4 - ... - 3 - 5 - 7 - 2 - 8 - 3 - 33
- A/H1N1 v - ... - 3 - 3 - ... - 4 - 18 - 36 - 69 - 149 - 245 - 256 - 204 - 230 - 1.217
- INFLUENZA B - 0 - 2 - 2 - 1 - 7 - 12 - 17 - 28 - 36 - 58 - 102 - 91 - 93 - 449
- TOTAL POSITIVE SAMPLES - 0 - 6 - 5 - 2 - 15 - 32 - 58 - 101 - 213 - 342 - 393 - 331 - 349 - 1.847
ANTIVIRAL DRUGS RESISTANCE SURVEILLANCE - ITALY
Since the start of the 2010/2011 influenza season, forty three (43) influenza A(H1N1) 2009 viruses have been tested for antivirals susceptibility; among these, two (2) (4.6%) were resistant to the neuraminidase inhibitor oseltamivir but retained susceptibility to zanamivir.
The two viruses were collected from two hospitalized children in Parma, who were treated with the drug oseltamivir.
Genetic sequence analysis revealed that the two viruses possessed the H274Y substitution on neuraminidase, that confers resistance to oseltamivir.
Drug resistance was confirmed for these viruses through enzyme assays (MUNANA).
In addition, four A(H3N2) and 28 type B viruses have been confirmed susceptible to both oseltamivir and zanamivir.
(...)
-
-----